



HAL
open science

Systematic review and meta-analysis: Prognostic tests of paracetamol-induced acute liver failure

Darren George Norman Craig, Alexander Ford, Peter C Hayes, K J Simpson

► **To cite this version:**

Darren George Norman Craig, Alexander Ford, Peter C Hayes, K J Simpson. Systematic review and meta-analysis: Prognostic tests of paracetamol-induced acute liver failure. *Alimentary Pharmacology & Therapeutics*, 2010, <10.1111/j.1365-2036.2010.04279.x>. <hal-00552537>

HAL Id: hal-00552537

<https://hal.science/hal-00552537v1>

Submitted on 6 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Systematic review and meta-analysis: Prognostic tests of paracetamol-induced acute liver failure

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0039-2010.R1
Manuscript Type:	Systematic Review
Date Submitted by the Author:	20-Feb-2010
Complete List of Authors:	Craig, Darren; Royal Infirmary of Edinburgh, Scottish Liver Transplant Unit Ford, Alexander; St James's University Hospital, Department of Academic Medicine Hayes, Peter; Royal Infirmary of Edinburgh, Scottish Liver Transplant Unit Simpson, K; Royal Infirmary of Edinburgh, Scottish Liver Transplant Unit
Keywords:	Drug-induced liver disease < Hepatology, Liver < Organ-based, Meta-analyses < Topics, Liver transplantation < Hepatology

1
2
3 **Systematic review and meta-analysis: Prognostic tests of paracetamol-**
4 **induced acute liver failure**
5

6
7 **D G N Craig¹, A C Ford², P C Hayes¹, K J Simpson¹**
8
9

10
11 ¹Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK
12

13 ²Department of Academic Medicine, St James's University Hospital, Leeds, UK
14
15

16
17 Corresponding author:
18

19 Dr Kenneth James Simpson
20

21 Scottish Liver Transplantation Unit
22

23 Royal Infirmary of Edinburgh
24

25 Little France
26

27 EDINBURGH
28

29 EH16 4SA
30
31

32 Telephone 00441312421717
33

34 Fax: 00441312421633
35

36 Email: k.simpson@ed.ac.uk
37
38

39 Competing Interest: None to declare
40
41

42 Funding sources: None to declare
43
44

45 **Keywords** Liver transplantation; King's College Criteria; acetaminophen; acute liver
46 failure
47

48 **Word count** 2939
49
50
51
52
53
54
55
56
57
58
59
60

ABBREVIATIONS

AFP	Alpha-fetoprotein
ALF	Acute liver failure
ALT	Alanine aminotransferase
APACHE II	Acute Physiology and Chronic Health Evaluation II
AUC	Area under the curve
DOR	Diagnostic odds ratio
HE	Hepatic encephalopathy
IL-6	Interleukin-6
KCC	King's College Criteria
KCH	King's College Hospital
MELD	Model for End-Stage Liver Disease
OLT	Orthotopic liver transplantation
ROC	Receiver operating characteristics
SIRS	Systemic inflammatory response syndrome
SOFA	Sequential Organ Failure Assessment

ABSTRACT

Background: Paracetamol toxicity remains the leading cause of acute liver failure (ALF) in the developed world. In the UK, the recently modified King's College Criteria (KCC) are used to list patients for emergency liver transplantation, but these criteria have been criticised for their low sensitivity and for spectrum bias in their application.

Aim: To critically evaluate existing prognostic criteria for predicting death without transplantation in paracetamol-induced ALF.

Methods: MEDLINE, EMBASE and CINAHL were searched to identify studies containing adult patients with paracetamol-induced ALF. Selected studies were evaluated, and data were pooled if appropriate, to calculate sensitivity, specificity, and diagnostic odds ratios (DORs) of applied prognostic tests.

Results: Of 6507 studies identified, 14 were eligible for inclusion, evaluating 1960 patients. The original KCC had a pooled sensitivity of 58.2% and specificity of 94.6%, with a DOR of 27.7. Addition of arterial lactate to the KCC reduced the DOR to 26.1. **Several other clinical and laboratory variables** had higher DORs than the KCC, but were only evaluated in single studies of limited quality.

Conclusion: **The original KCC remain well validated criteria with high prognostic accuracy.** Other potential prognostic variables should be prospectively assessed in multi-centre studies to further refine the criteria.

INTRODUCTION

1
2
3
4
5
6
7 Paracetamol (acetaminophen) toxicity remains the leading cause of acute
8 liver failure (ALF) in the developed world, accounting for over 40% of cases in
9 selected case series.(1,2) Whilst the vast majority of patients recover spontaneously
10 following paracetamol overdose, a small number develop severe acute liver injury,
11 hepatic encephalopathy (HE) and consequently, ALF. Despite significant advances
12 in supportive care, the only effective treatment for the condition remains emergency
13 orthotopic liver transplantation (OLT).(3)

14
15
16
17
18
19
20
21
22
23
24 The decision to transplant a patient with paracetamol-induced ALF involves
25 balancing the inherent risks associated with delaying listing for OLT against the
26 potential for spontaneous recovery with medical therapy alone, the risks of surgery in
27 the context of a rapidly evolving critical illness, the scarcity of donor grafts, and the
28 requirement for lifelong immunosuppression. Furthermore, the psychosocial
29 implications of paracetamol overdose cases are considerable, with over 30% of
30 patients that fulfil transplant criteria unsuitable for OLT due to severe psychological
31 illness, or coexistent chronic alcohol or drug dependency.(4) Accurate
32 prognostication in ALF is therefore vital to utilise OLT effectively and prevent
33 unnecessary transplantation, whilst procuring donor organs in a timely fashion for
34 those most likely to benefit.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51 In 1989 O'Grady and colleagues developed the 'King's College Criteria' (KCC)
52 in an attempt to determine which patients with paracetamol and non-paracetamol-
53 induced ALF have a poor prognosis with medical therapy alone, and will therefore
54 benefit most from OLT.(5) The original KCC for paracetamol-induced ALF were
55 highly specific, but have been criticised for their relatively low negative predictive
56
57
58
59
60

1
2
3 value (6) and, since up to 26% of patients with paracetamol toxicity are medically
4 unfit to undergo surgery at the point they fulfil the KCC,(4) modifications to these
5 criteria now utilise arterial lactate (>3.5 mmol/L after early fluid resuscitation or >3.0
6 mmol/L after adequate fluid resuscitation) in an attempt to extend the time-window
7 for acquisition of a suitable graft.(7)
8
9
10
11
12
13
14
15

16 Over recent years a plethora of alternative prognostic variables have been
17 proposed, in an attempt to improve, or replace, the KCC. These criteria variously
18 involve radiological,(8) histological,(9) serological,(10,11) or mathematical (12-14)
19 indices, but their assessment is complicated by the use of OLT; due to the inevitably
20 imperfect nature of current listing criteria a small proportion of ALF patients are
21 transplanted who would have spontaneously survived, invalidating further
22 assessment of that particular patient. Studies evaluating the prognostic accuracy of
23 a particular variable should therefore exclude transplanted patients from subsequent
24 analysis. The purpose of this systematic review was to critically evaluate existing
25 prognostic criteria for predicting death without transplantation in paracetamol-
26 induced ALF, to update previous studies in this area,(15,16) and to examine the
27 accuracy of recently described prognostic variables.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search Strategy and Study Selection

We conducted a systematic review of the medical literature using MEDLINE (1950 to June 2009), EMBASE (1980 to June 2009), and CINAHL (1982 to June 2009) to identify studies recruiting adult (>age 16 years) patients that evaluated prognostic markers of paracetamol-induced ALF. Potential studies were identified by combining the search terms “acetaminophen” and “paracetamol” (as both Medical Subject Headings (MeSH) and free text terms) using the set operator OR.

Prognostic studies of ALF were identified, and combined using the set operator OR, by using the terms “Kings adj3 College adj3 Criteria”, “Clichy\$”, “APACHE\$”, “lactate”, “Gc-globulin”, “alpha-fetoprotein”, “phosphate” and “MELD” (all free text terms) and the McMaster expert search strategy for prognostic studies. These studies were combined using the set operator AND with papers evaluating studies on “liver failure”, “hepatic encephalopathy” or “liver failure, acute” (all MeSH). The search was limited to human studies without language restrictions. Abstracts of the studies identified by the initial search were evaluated for appropriateness to the study question by two independent reviewers (DC, KS) and all potentially relevant papers were obtained and evaluated in detail. The bibliographies of these studies and relevant review articles were screened to perform a recursive search of the literature, and abstract books of international liver conferences from the preceding 4 years were hand-searched for potentially relevant studies.

Selected studies were required to report mortality data on cohorts of patients admitted to hospital with acute severe liver injury or ALF secondary to paracetamol overdose (**see Box for study eligibility criteria**). Acute severe liver injury was defined as severe hepatotoxicity (serum alanine aminotransferase (ALT) levels >1000

1
2
3 U/mL and co-existent coagulopathy), whilst ALF required the additional presence of
4
5 HE, in patients without pre-existing liver disease. Unselected cohorts of patients with
6
7 mixed etiologies of acute liver injury were eligible for inclusion if separate data for
8
9 paracetamol overdose patients were available. Case control studies and studies
10
11 comparing ALF patients with chronic liver disease patients were excluded due to
12
13 potential bias in favour of the prognostic variable in question,(17) as were studies
14
15 where transplantation and death were combined as a single end-point. Studies were
16
17 required to include more than 25 patients with paracetamol-induced acute liver
18
19 injury, since the majority of studies in this area include the KCC as a prognostic
20
21 variable in addition to the main variable studied, and smaller studies may invalidate
22
23 analysis.(18) All potential articles were assessed independently by two researchers
24
25 according to eligibility criteria, which were defined prospectively, and disagreements
26
27 resolved by consensus.
28
29
30
31
32
33
34
35
36

37 **Data extraction and quality assessment**

38
39
40 Data were extracted using predesigned forms by two separate reviewers (DC
41
42 and KS) on to a Microsoft Excel spreadsheet (Microsoft Corp, Redmond, WA, USA),
43
44 and any discrepancies were resolved by consensus. The following data were
45
46 extracted for each study: setting, country and geographical region, year(s)
47
48 conducted, retrospective or prospective design, inclusion criteria, definitions of
49
50 paracetamol-induced liver injury, definitions of ALF, total number of subjects
51
52 included, total number of subjects with paracetamol-induced ALF or acute liver
53
54 injury, total number of subjects with paracetamol-induced ALF transplanted, duration
55
56 of follow-up, prognostic score used, timing of application of the prognostic score, and
57
58 outcome definitions. Study quality was assessed semi-quantitatively according to six
59
60

potential sources of bias that can be encountered in studies of prognostic variables (19) and a grade (poor, moderate, good or excellent) allocated (**Table 1**).

Study population	Study population adequately represents the population of interest; source population adequately described; sampling timeframe, place and period of recruitment described; inclusion and exclusion criteria described
Follow-up	Adequate study completion rate; loss to follow-up not associated with key characteristics; reasons for loss to follow-up described; no important differences between participants completing/not completing study
Prognostic factor	Prognostic measure clearly defined; continuous data reported and any cut-points described and appropriate; method and setting of measurement of prognostic factor identical for all patients; adequate proportion of study population has prognostic factor measured
Outcome measurement	Clear definition of outcome measure of interest described and recorded, including duration of follow-up; outcome measure valid; outcome measure identical
Confounding	All important confounders measured and accounted for at all stages of study design, performance and analysis
Analysis	Sufficient presentation of data to permit assessment of analytical analysis; appropriate model-building, study design etc.; no selective reporting of results

Table 1 Quality assessment of included studies (adapted from Hayden 2006 (19))

Data synthesis and analysis

Prognostic tests evaluating the outcomes of survival without transplantation or death without transplantation following paracetamol-induced liver injury were assessed individually. From each study cohort we extracted total number of subjects dying without OLT, total number of subjects surviving without OLT, and total

1
2
3 numbers of subjects fulfilling or not fulfilling the prognostic variable in question, and
4 constructed 2x2 contingency tables. The sensitivity, specificity, and diagnostic odds
5 ratio (DOR) with their 95% confidence intervals (CI) were calculated for each test
6 using Microsoft Excel (Microsoft Corp, Redmond, Washington, USA) and checked
7 using Meta-DiSc version 1.4 (Universidad Complutense, Madrid, Spain). The value
8 of a DOR ranges from zero to infinity, with higher values indicating better
9 discriminatory test performance, and is calculated from the following formula:
10 $\text{sensitivity}/(1 - \text{sensitivity}) / (1 - \text{specificity})/\text{specificity}$.(20) Where required, a zero cell
11 correction of 0.5 was added to all cells to prevent computational problems arising
12 where proportions were equal to zero.(21) Where two or more studies analysed a
13 particular prognostic marker, data were pooled using a random effects model and
14 the pooled DOR calculated. Heterogeneity between studies was assessed using the
15 I^2 statistic with a cut off of 50%, and the χ^2 test with a P value < 0.10, used to define
16 a statistically significant degree of heterogeneity. We explored study setting and
17 study design as potential reasons for heterogeneity.(22) These are exploratory
18 analyses only, and the results should therefore be interpreted with caution.

44 RESULTS

45
46
47 The search strategy identified 6507 studies of which 105 were potentially
48 eligible for inclusion and were retrieved for further analysis (**Figure 2**). Of these, 14
49 were considered eligible for inclusion,(5,7,10,23-33) including two studies published
50 in abstract form only.(32,33) Characteristics of included studies are provided in
51
52
53
54
55
56
57 **Table 2.** Cohen's kappa test for inter-observer agreement was excellent at 0.86
58 (95% CI 0.75-0.98).
59
60

Study	Country	Liver Unit	Study period	Inclusion criteria	Prognostic test(s) evaluated	No paracetamol patients included	Retrospective/prospective cohort	Retrospective/prospective test development/evaluation	Study quality
O'Grady 1989(5)	UK	KCH	1973-1985; 1986-7	FHF as per Trey & Davidson(34) with Grade III-IV HE	pH<7.3 Concurrent PT>100 seconds, serum creatinine> 300 mmol/L, Grade III/IV HE	121 99	Both	Prospective	Moderate
O'Grady 1991(23)	UK	KCH	1988-1990	Severe liver damage	KCC as per O'Grady (5)	60	Prospective	Prospective	Moderate
Izumi 1996 (24)	UK	KCH	Not stated	FHF as per Trey & Davidson (34)	KCC as per O'Grady (5) Factor V ratio <20% Factor V ratio <10%	} 81	Prospective	Prospective (partially)	Poor
Anand 1997(25)	UK	Birmingham	1990-1994	FHF as per Trey & Davidson (34)	pH<7.3 Concurrent PT>100 seconds, serum creatinine> 300 mmol/L, Grade III/IV HE	72 89	Retrospective	Prospective	Poor
Bernal 1998(26)	UK	KCH	1990-1996	Severe hepatotoxicity (KCC); Death whilst not meeting KCC (APACHE III)	KCC as per O'Grady(5) Adapted APACHE III	504 56	Retrospective	Prospective (KCC) Retrospective (APACHE III)	Poor
Mitchell 1998(27)	UK	KCH	1993-1994	Coagulopathy + recent history paracetamol ingestion	KCC as per O'Grady(5) APACHE II>15 at 24 hr post-admission APACHE II>15	} 94	Prospective	Prospective (KCC) Retrospective (APACHE II)	Good
Bernal 2002(7)	UK	KCH	1998-1999 (learning set) 1999-2000 (validation set)	Severe paracetamol-induced hepatotoxicity	KCC as per O'Grady(5) Arterial lactate>3.5 mmol/L at 4 hours Arterial lactate>3.0 mmol/L at 12 hours	99 97 85	Both	Prospective	Moderate

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

					KCC + combination of lactate criteria	85			
Bernal 2003(28)	UK	KCH	1998-2000	Acute severe hepatotoxicity	KCC as per O'Grady(5) Phosphate >1.2 mmol/L on admission day +1 or 2	} 170	Retrospective	Prospective	Moderate
Larson 2005(29)	USA	22 academic centres	1998-2003	INR>1.4; HE; jaundice to HE interval<26 weeks	KCC as per O'Grady(5)	252	Prospective	Prospective	Moderate
Schmidt 2005(10)	Denmark	Copenhagen	1999-2002	Peak ALT>1000U/L	KCC as per O'Grady(5) AFP <3.9 at D1 post peak ALT AFP <3.9 & INR>2.4 at D1 post peak ALT	234 188 188	Prospective	Prospective (KCC) Retrospective (AFP)	Moderate
Schmidt 2006(30)	Denmark	Copenhagen	1999-2004	Severe paracetamol-induced FHF	KCC as per O'Grady(5) Arterial lactate Modified KCC SOFA score >8 at admission/ >12 at onset of Grade III/IV HE SIRS at admission/at onset of Grade III/IV HE	95 91 91 95 95	Prospective	Retrospective	Moderate
Zaman 2006(31)	Ireland	Dublin	1994-2005	Paracetamol-induced ALF (jaundice to HE <8 weeks) or rapid bilirubin/ INR/ renal impairment/ hypoglycaemia if no HE	KCC as per O'Grady(5) MELD >30	} 60	Retrospective	Prospective	Poor
Bates 2007(32)	UK	Edinburgh	2004-2007	Acute severe liver injury	KCC as per O'Grady(5) Lactate modifications to KCC as per Bernal(7)	69 32	Retrospective	Prospective	Poor
Bernal 2007(33)	UK	KCH	Not stated	Acute liver failure	IL-6 within 24 hours of admission	31	Prospective	Retrospective	Poor

Table 2 Characteristics of included studies

PT, prothrombin time; FHF, fulminant hepatic failure

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3 The eligible studies evaluated a total of 1960 patients with paracetamol-
4 induced acute liver injury or ALF. Three (10,24,27) studies had complete temporal
5 overlap with other studies from the same unit; however, these studies were included
6 for their evaluation of unique prognostic markers separate to the KCC. There was
7 only one multicentre study.(29) Five (25,26,28,31,32) studies evaluated patient
8 cohorts retrospectively, whilst five (10,26,27,30,33) studies developed prognostic
9 test thresholds retrospectively (usually from receiver operator characteristics (ROC)
10 curve analysis). No studies blinded observers to patient outcome or other potentially
11 confounding prognostic data; and only two (5,7) validated their prognostic marker in
12 a separate cohort. Consequently, six (24-26,31-33) of the 14 studies were graded as
13 poor and seven (5,7,10,23,28-30) as moderate quality (**Table 2**). The 14 eligible
14 studies analysed a total of 22 different prognostic markers or variations thereof. The
15 sensitivity, specificity, and DORs of these are reported in **Table 3**.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Prognostic test	Study	N/deaths	Test +ve/ deaths	Sensitivity (95% CIs)	Specificity (95% CIs)	Diagnostic Odds Ratio (95% CIs)	Heterogeneity	
							χ^2	I^2
pH<7.3	O'Grady 1989(5)	121/43	22/21	48.8 (33.3-65.5)	98.7 (93.1-100)	73.5 (9.4-577.4)	4.91 p=0.027	80%
	Anand 1997(25)	72/39	31/24	61.5 (44.6-76.6)	78.8 (61.1-91.0)	5.9 (2.1-17.1)		
	POOLED			54.9 (43.5-65.9)	92.8 (86.3-96.8)	18.0 (1.1-229.6)		
Concurrent PT>100s, serum creatinine>300 mmol/L, Grade III/IV HE	O'Grady 1989(5)	99/22	15/10	45.5 (24.4-67.8)	93.5 (85.5-97.9)	12.0 (3.5-41.3)	0.8 p=0.374	0%
	Anand 1997(25)	89/45	24/19	42.2 (27.7-57.9)	88.6 (75.4-96.2)	5.7 (1.9-17.2)		
	POOLED			43.3 (31.2-56.0)	91.7 (85.3-96.0)	7.9 (3.5-18.1)		
KCC (combined)†	O'Grady 1989(5)	220/65	37/31	47.7 (35.1-60.5)	96.1 (91.8-98.6)	22.6 (8.8-58.6)	8.4 p=0.038	64%
	O'Grady 1991(23)	60/26	23/19	73.1 (52.2-88.4)	88.2 (72.6-96.7)	20.4 (5.2-79.0)		
	Bernal 1998(26)	504/99	80/71	71.7 (61.8-80.3)	97.8 (95.8-99.0)	111.6 (50.5-246.4)		
	Bernal 2002(7)	99/21	20/16	76.2 (52.8-91.8)	94.9 (87.4-98.6)	59.2 (14.3-245.3)		
	POOLED (KCH)			65.9 (59.0-72.3)	96.1 (94.4-97.5)	43.9 (17.6-109.3)		
	Larson 2005(29)							
	(at admission)	252/74	34/19	25.7 (16.2-37.2)	91.6 (86.5-95.2)	3.8 (1.8-7.9)		
	Schmidt 2006(30)	95/48	36/27	77.1 (62.7-88.0)	83.0 (69.2-92.4)	16.4 (5.9-45.3)		
	Zaman 2006(31)	60/29	21/21	72.4 (52.8-87.3)	100.0 (88.8-100.0)	159.4 (8.7-2908.9)		
Bates 2007(32)	69/17	18/15	88.2 (63.6-98.5)	94.2 (84.1-98.8)	122.5 (18.7-803.1)			
POOLED (non-								

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	KCH)			48.8 (41.0-56.6)	91.2 (87.5-94.1)	16.5 (3.5-77.8)	17.0 p=0.001	82%
	POOLED (overall)			58.2 (53.1-63.3)	94.6 (93.0-95.9)	27.7 (9.2-83.5)	53.0 p<0.001	87%
	Bernal 2002(7)	97/21	18/14	66.7 (43.0-85.4)	94.7 (87.1-98.6)	36.0 (9.3-139.6)		
Arterial lactate >3.5 at admission	Schmidt 2006(30)	91/46	61/39	84.8 (71.1-93.7)	51.1 (35.8-66.3)	5.8 (2.2-15.8)	4.54 p=0.103	56%
	Bates 2007(32)	69/17	37/15	88.2 (63.6-98.5)	57.7 (43.2-71.3)	10.2 (2.1-49.4)		
	POOLED			81.0 (70.9-88.7)	72.3 (64.9-78.8)	12.2 (4.0-37.4)		
	Bernal 2002(7)	85/21	18/16	76.2 (52.8-91.8)	96.9 (89.2-99.6)	99.2 (17.6-559.3)		
Arterial lactate >3.0 following resuscitation	Schmidt 2006*(30)	91/46	55/36	78.3 (63.6-89.1)	57.8 (42.2-72.3)	4.9 (2.0-12.3)	9.83 p=0.007	80%
	Bates 2007(32)	32/12	20/12	100.0 (73.5-100.0)	60.0 (36.1-80.9)	36.8 (1.9-708.0)		
	*at onset of Grade III/IV HE							
	POOLED			81.0 (70.6-89.0)	77.5 (69.3-84.4)	22.8 (2.5-210.0)		
Arterial lactate >4.0 at admission			51/34	73.9 (58.9-85.7)	62.2 (46.5-76.2)	4.7 (1.9-11.4)		
Arterial lactate >4.0 at onset of Grade III/IV HE	Schmidt 2006 (30)	91/46	40/31	67.4 (52.0-80.5)	80.0 (65.4-90.4)	8.3 (3.2-21.5)	-	-
	Bernal 2002(7)	85/21	24/19	90.5 (69.6-98.8)	92.2 (82.7-97.4)	112.1 (20.1-625.7)		
KCC + arterial lactate >3.0 following resuscitation	Schmidt 2006(30)	91/46	69/42	91.3 (79.2-97.6)	40.0 (25.7-55.7)	7.0 (2.1-22.9)	8.83 p=0.003	89%
	POOLED			91.0 (81.5-96.6)	70.6 (61.2-79.0)	26.1 (1.7-393.7)		

Factor V ratio <20%	Izumi 1996(24)	81/35	69/34	97.1 (85.1-99.9)	23.9 (12.6-38.8)	10.7 (1.3-87.3)	-	-
Factor V ratio <10%			51/29	63.0 (47.6-76.8)	37.1 (21.5-55.1)	5.3 (1.8-15.1)	-	-
Adapted APACHE III	Bernal 1998(26)	56/28	19/16	57.1 (37.2-75.5)	89.3 (71.8-97.7)	11.1 (2.7-45.6)	-	-
APACHE II>15 at 24 hr post- admission	Mitchell 1998(27)	94/14	13/11	78.6 (49.2-95.3)	97.5 (91.3-99.7)	143.0 (21.4 -953.5)	-	-
APACHE II>15 within 5 days of admission			23/13	92.9 (66.1-99.8)	87.5 (78.2-93.8)	91.0 (10.7-772.8)	-	-
Phosphate >1.2 mmol/L on admission day +1 or 2	Bernal 2003(28)	170/52	55/42	80.8 (67.5-90.4)	89.0 (81.9-94.0)	33.9 (13.8-83.3)	-	-
AFP <3.9 at D1 post peak ALT	Schmidt 2005(10)	188/33	54/33	100.0 (89.4-100.0)	73.6 (65.9-80.3)	184.9 (11.1-3085.6)	-	-
AFP <3.9 & INR>2.4 at D1 post peak ALT			74/33	100.0 (89.4-100.0)	86.5 (80.0-91.4)	419.1 (24.8-7097.5)	-	-
SOFA score >8 at admission	Schmidt 2006(30)	95/48	48/32	66.7 (51.6-79.6)	66.0 (50.7-79.1)	3.9 (1.7-9.1)	-	-
SOFA score >12 at onset of Grade III/IV HE			54/39	81.3 (67.4-91.1)	68.1 (52.9-80.9)	9.2 (3.6-23.9)	-	-

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

SIRS at admission	Schmidt 2006(30)	95/48	52/33	68.8 (53.7-81.3)	59.6 (44.3-73.6)	3.2 (1.4-7.5)	-	-
SIRS at onset of Grade III/IV HE			41/34	70.8 (55.9-83.0)	85.1 (71.7-93.8)	13.9 (5.0-38.3)		
MELD >30	Zaman 2006(31)	60/29	38/28	96.6 (82.2-99.9)	67.7 (48.6-83.3)	58.8 (7.0-495.8)	-	-
IL-6 within 24 hours of admission	Bernal 2007(33)	31/8	7/6	75.0 (34.9-96.8)	95.7 (78.1-99.9)	66.0 (5.1-857.7)	-	-

Table 3 Sensitivity, specificity, and diagnostic odds ratios of individual prognostic markers.

† Anand 1997 (25) excluded as 2x2 table not reconstructable; Mitchell 1998,(27) Bernal 2003,(28) and Schmidt 2005(10) excluded due to complete temporal overlap with previous studies from same unit

King's College Criteria

A total of 13 studies evaluated the original KCC for paracetamol-induced ALF, either as separate elements (arterial pH<7.3 or concurrent grade III/IV HE, serum creatinine>300µmol/L and prothrombin time (PT)>100 seconds) (5,25) or as a whole, (7,10,23,24,26-32) including a total of 1929 patients. One study (29) evaluated the KCC only on admission. After exclusion of studies with complete temporal overlap with other studies,(10,24,27) pooled specificity of the KCC was high, at 94.6% (95% CI 93.0-95.9), but the pooled sensitivity was relatively poor at 58.2% (95% CI 53.1-63.3). The pooled DOR for the KCC was 27.7 (95% CI 9.2-83.5) (**Table 3**). The summary ROC curve is shown in **Figure 3**. The area under the curve (AUC) was calculated as 0.91 (95% CI 0.79-0.99), suggesting good performance of the KCC overall.(35) The accuracy of the KCC improved when studies originating from KCH were analysed separately from those outside KCH (DOR 43.9 (95% CI 17.6-109.3) for KCH-based studies vs. DOR 16.5 (95% CI 3.5-77.8) for non-KCH-based studies). Statistically significant heterogeneity ($I^2=87\%$) existed between individual study results, though this fell to 79% after exclusion of the single multi-centre study,(29) and to 64% after exclusion of studies from outside KCH.

Lactate modifications to the KCC

The original study (7) that evaluated arterial lactate in the prognosis of paracetamol-induced ALF reported similar specificity, but improved sensitivity, when compared with the original KCC. However, two (30,32) subsequent studies evaluating arterial lactate alone failed to replicate this high prognostic accuracy (**Table 3**), with pooled DORs of 12.2 (95% CI 4.0-37.4) and 22.8 (95% CI 2.5-210.0)

1
2
3 for the early and post-resuscitation lactate values respectively. This was mainly due
4 to the reduced specificity seen in the two studies from outside KCH. Combination of
5 the KCC with a post-resuscitation lactate value >3.0 offered higher prognostic
6 accuracy in the original lactate study (7) but this was not replicated in a subsequent
7 evaluation.(30)
8
9
10
11
12
13
14
15
16
17
18

19 **Other prognostic markers**

20
21
22 Several other markers, all evaluated in single studies, appeared to offer
23 improved prognostic accuracy when compared with the KCC, with low serum alpha-
24 fetoprotein (AFP) (DOR 419.1),(10) 24-hour post-admission Acute Physiology and
25 Chronic Health Evaluation II (APACHE II) score (DOR 143.0),(27) serum interleukin-6
26 (IL-6) levels (DOR 66.0),(33) Model for End-Stage Liver Disease (MELD) score
27 (DOR 58.8),(31) and serum phosphate (DOR 33.9) (28) all outperforming the KCC
28 (**Table 3**). However, further studies would be required to replicate these findings to
29 confirm or refute whether these other markers are indeed superior to the KCC.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **DISCUSSION**

46
47
48 This systematic review and meta-analysis has demonstrated that the original
49 KCC for paracetamol-induced ALF have high pooled specificity (94.6%), but low
50 pooled sensitivity (58.2%) in determining prognosis in patients with paracetamol-
51 induced ALF. Additionally, the benefit of the arterial lactate modifications to the KCC
52 (7) is questionable according to these data. Other proposed prognostic markers, in
53
54
55
56
57
58
59
60

1
2
3 particular AFP, APACHE II scores, and serum IL-6 levels, showed encouraging
4 prognostic accuracy but were only evaluated in single studies of variable quality.
5
6
7

8
9 This review is limited by the quality of the included studies, which had
10 significant heterogeneity and were generally of poor or moderate quality, with only
11 two (5,7) studies validating their prognostic model prospectively in a separate cohort.
12
13 Acute liver failure is a rare syndrome and, as a result, many studies were small and
14 retrospective in nature. Continuous variables were frequently analysed
15 retrospectively using cut-off values designed to maximise AUC values, a method
16 which assumes constant risk amongst the 'high' and 'low' risk groups.(18) Several
17 studies attempted to evaluate multiple prognostic markers retrospectively using the
18 same cohort, an approach which increases the risk of obtaining a statistically
19 significant result by chance. **Another potentially confounding issue is the lack of
20 international standardisation of laboratory variables, such as prothrombin time and
21 creatinine, and changes to assay reagents over the time course of these studies.(36)**
22
23 We also appreciate that exclusion of studies where transplantation and death were
24 deemed equivalent may have introduced spectrum bias, since prognostic tests are
25 usually applied in settings where OLT is available. This problem is difficult to
26 circumvent given that emergency OLT will never be subjected to a clinical trial, but,
27 given the reduced quality-of-life seen following transplantation for paracetamol-
28 induced ALF, the accumulated risks of immunosuppression, and the scarcity of liver
29 donors,(16) accurate calculation of the specificity of each prognostic test is vital in
30 order to minimise inappropriate transplantation.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56
57 This study expands upon a recent systematic review (16) evaluating the KCC
58 for paracetamol-induced ALF by including additional prognostic markers. The former
59 study found spectrum bias in studies originating from KCH, with increased
60

1
2
3 spontaneous survival amongst patients listed for transplantation, but not receiving a
4 graft, compared with those meeting criteria but never listed, suggesting that a
5
6 'healthier' cohort may be preferentially transplanted in KCH. The current data confirm
7
8 the increased prognostic accuracy of the original KCC in studies originating from
9
10 KCH compared with studies from other units, with a higher pooled DOR in KCH-
11
12 based studies compared with that from studies conducted in other units. This raises
13
14 further questions regarding the overall generalisability of the KCC to patients with
15
16 paracetamol-induced ALF treated outside KCH.
17
18
19
20
21
22

23 The heterogeneity of the included studies evaluating the KCC was partly due
24
25 to a multicentre US study (29) which explicitly applied the KCC solely at the time of
26
27 admission, rather than dynamically throughout admission as originally
28
29 intended.(5,37) Whilst early and accurate prognostication in ALF is vital in order to
30
31 permit timely listing for OLT, application of the KCC solely at admission reduces the
32
33 time available for the disease to evolve and may introduce spectrum bias. Given that
34
35 the median time taken to fulfil the KCC following admission to a tertiary liver
36
37 transplant unit is 12 hours,(7) application of the KCC solely at admission may explain
38
39 the low sensitivity of the criteria in the US study, whilst concerns have also been
40
41 expressed about the prophylactic use of fresh frozen plasma in this US study and the
42
43 potential confounding effects upon prothrombin time.(38) Furthermore, 48% of cases
44
45 resulted from unintentional overdoses in this US study, a type of overdose seen less
46
47 frequently in the UK.(39) It may be that repeated ingestion of supratherapeutic
48
49 doses of paracetamol over a protracted time course disrupts liver function
50
51 subacutely, so that patients are less likely to develop the profound acidosis or
52
53 concurrent severe coagulopathy, renal dysfunction, and encephalopathy required to
54
55 fulfil the KCC, but have at least as poor a prognosis as an intentional overdose at a
56
57
58
59
60

1
2
3 single time point. Future prognostic scoring systems may therefore need to take the
4
5 pattern of paracetamol overdose into account in addition to traditional biochemical
6
7 parameters.
8
9

10
11 The addition of post-resuscitation arterial lactate to the KCC (7) is questioned
12
13 by this study. Only two additional (30,32) studies, one of which was reported in
14
15 abstract-form, that reported this modification fulfilled eligibility criteria for inclusion,
16
17 but these studies suggest little benefit from this. Furthermore, the reduced specificity
18
19 of the lactate criteria undermines the traditional benefit of the KCC in 'ruling in' a
20
21 hopeless prognosis. The presence of systemic inflammation, with or without sepsis,
22
23 is increasingly recognised as important in ALF,(40) but hyperlactataemia can result
24
25 from numerous other organ sources and therefore, perhaps not surprisingly, arterial
26
27 lactate is a relatively non-specific prognostic indicator in paracetamol-induced ALF.
28
29 Within critical care settings, the use of APACHE II and Sequential Organ Failure
30
31 Assessment (SOFA) scores to monitor organ dysfunction have greater recognition
32
33 than the KCC, and are attractive as early prognostic markers in ALF.(41) APACHE II,
34
35 in particular, showed encouraging prognostic accuracy but was only evaluated in a
36
37 single **eligible** study.(27) One (29) additional study evaluating APACHE II scores was
38
39 excluded from this particular analysis as the prognostic scoring reported in the study
40
41 could not be reconstructed into a 2x2 table; this study is also notable for the atypical
42
43 nature of the patient cohort as outlined above. Given that APACHE III, systemic
44
45 inflammatory response syndrome (SIRS) and SOFA scores all performed less well
46
47 than the KCC (albeit in single studies), the role of these markers may be to permit
48
49 earlier identification of a high-risk cohort requiring transfer to tertiary centres that
50
51 offer liver transplantation, rather than as definitive transplant listing criteria.
52
53
54
55
56
57
58
59
60

1
2
3 Persistently elevated serum phosphate or reduced AFP levels may reflect
4 failure of hepatic regeneration, and therefore could help predict a poorer outcome in
5 paracetamol-induced ALF. Serum AFP showed high prognostic performance in one
6 (10) study, whilst serum phosphate showed equivalence with the KCC in one (28)
7 retrospective study from KCH. Other authors, (in studies where transplantation was
8 equated with death and hence excluded from this study), have demonstrated
9 conflicting results with serum phosphate,(42-45) so further evaluation of both serum
10 AFP and phosphate in future studies would be worthwhile. The MELD scoring
11 system has been widely adopted for organ allocation in chronic liver disease and has
12 shown encouraging prognostic accuracy in non-paracetamol ALF.(12,46-48) More
13 limited data exist regarding the use of MELD in paracetamol-induced ALF, but one
14 additional study (excluded from this analysis as the 2x2 table was not
15 reconstructable) suggested that its use may be limited by a high false positive
16 rate.(49)

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37 In summary, this systematic review and meta-analysis has demonstrated that
38 the original KCC for paracetamol-induced ALF have high pooled specificity, but low
39 pooled sensitivity in determining prognosis in patients with paracetamol-induced
40 ALF. The KCC had reduced prognostic accuracy when applied outside of KCH and
41 were occasionally applied only at admission. The reduced specificity of the KCC
42 following the addition of arterial lactate calls into question the benefit of this
43 modification, suggesting that re-evaluation of this as a prognostic marker is required.
44 Urgent consideration should be given to the design of a high-quality, prospective
45 study evaluating the KCC, APACHE II scores, and markers of hepatic regeneration,
46 such as serum AFP and phosphate, in paracetamol-induced ALF. Given the
47 relatively rare nature of ALF, such a study is likely to require cooperation between
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 several large centres, and argues the need for a collaborative network of tertiary
4
5 hospitals experienced in the management and prognostication of ALF, similar to that
6
7 developed by the Acute Respiratory Distress Syndrome Network program.(50)
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7 **Figure legends**
8

9
10 **Figure 1** Eligibility criteria for included studies
11

12
13 **Figure 2** Flow diagram of assessment of studies identified in the systematic
14 review
15

16
17
18 **Figure 3** Summary receiver operator curve (SROC) of studies evaluating the
19 original KCC
20
21
22

23
24 AUC: Area under the curve; SE: Standard Error; Q: heterogeneity
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Competing Interest: None to declare
6
7

8 Funding sources: None to declare
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

- 1
2
3
4 (1) Ostapowicz G, Fontana RJ, Schiody FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective
5 study of acute liver failure at 17 tertiary care centers in the United States. *Ann.Intern.Med.* 2002 Dec
6 17;137(12):947-954.
- 7
8 (2) Bernal W, Cross TJ, Auzinger G, Sizer E, Heneghan MA, Bowles M, et al. Outcome after wait-listing
9 for emergency liver transplantation in acute liver failure: a single centre experience. *J.Hepatol.* 2009
10 Feb;50(2):306-313.
- 11
12 (3) Craig DG, Lee A, Hayes PC, Simpson KJ. Review article: the current management of acute liver
13 failure. *Aliment.Pharmacol.Ther.* 2010;31(3):345-358.
- 14
15 (4) Simpson KJ, Bates CM, Henderson NC, Wigmore SJ, Garden OJ, Lee A, et al. The utilization of liver
16 transplantation in the management of acute liver failure: comparison between acetaminophen and
17 non-acetaminophen etiologies. *Liver Transplantation* 2009;15:600-609.
- 18
19 (5) O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant
20 hepatic failure. *Gastroenterology* 1989;97(2):439.
- 21
22 (6) Renner EL. How to decide when to list a patient with acute liver failure for liver transplantation?
23 Clichy or King's College criteria, or something else? *J.Hepatol.* 2007 Apr;46(4):554-557.
- 24
25 (7) Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in
26 paracetamol-induced acute liver failure: a cohort study. *Lancet* 2002 Feb 16;359(9306):558-563.
- 27
28 (8) Yamagishi Y, Saito H, Tada S, Horie Y, Kato S, Ishii H, et al. Value of computed tomography-
29 derived estimated liver volume/standard liver volume ratio for predicting the prognosis of adult
30 fulminant hepatic failure in Japan. *J.Gastroenterol.Hepatol.* 2005 Dec;20(12):1843-1849.
- 31
32 (9) Baeg N-, Bodenheimer J, H.C, Burchard K. Long-term sequellae of acetaminophen-associated
33 fulminant hepatic failure: Relevance of early histology. *Am.J.Gastroenterol.* 1988;83(5):569-571.
- 34
35 (10) Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced
36 liver injury. *Hepatology* 2005 Jan;41(1):26-31.
- 37
38 (11) Schiody FV, Rossaro L, Stravitz RT, Shakil AO, Chung RT, Lee WL, et al. Gc-globulin and prognosis
39 in acute liver failure. *Liver Transplantation* 2005 Oct;11(10):1223-1227.
- 40
41 (12) Kremers WK, Van Ijperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, et al. MELD Score as
42 a Predictor of Pretransplant and Posttransplant Survival in OPTN/UNOS Status 1 Patients.
43 *Hepatology* 2004 Mar;39(3):764-769.
- 44
45 (13) Yantorno SE, Kremers WK, Ruf AE, Trentadue JJ, Podestá LG, Villamil FG. MELD is superior to
46 King's college and Clichy's criteria to assess prognosis in fulminant hepatic failure. *Liver*
47 *transplantation* 2007;13(6):822.
- 48
49 (14) Cholongitas EB, Betrossian A, Leandro G, Shaw S, Patch D, Burroughs AK. King's criteria, APACHE
50 II, and SOFA scores in acute liver failure. *Hepatology* 2006 author reply 882; Apr;43(4):881.
- 51
52 (15) Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen
53 poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for
54 liver transplantation. *Crit.Care Med.* 2003 Jan;31(1):299-305.
- 55
56
57
58
59
60

1
2
3 (16) Ding GK, Buckley NA. Evidence and consequences of spectrum bias in studies of criteria for liver
4 transplant in paracetamol hepatotoxicity. QJM 2008 Sep;101(9):723-729.

5
6
7 (17) Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001 Jul
8 28;323(7306):224-228.

9
10 (18) Perel P, Edwards P, Wentz R, Roberts I. Systematic review of prognostic models in traumatic
11 brain injury. BMC Medical Informatics & Decision Making 2006;6:38.

12
13 (19) Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic
14 reviews. Annals of internal medicine 2006;144(6):427.

15
16 (20) Glas AS, Lijmer JG, Prins MH, Bossel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator
17 of test performance. J.Clin.Epidemiol. 2003 Nov;56(11):1129-1135.

18
19 (21) Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been
20 examined in systematic reviews of diagnostic test accuracy. Health Technol.Assess. 2005 iii;
21 Mar;9(12):1-113.

22
23 (22) Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ
24 2003 Sep 6;327(7414):557-560.

25
26 (23) O'Grady JG, Wendon J, Tan KC, Potter D, Cottam S, Cohen AT, et al. Liver transplantation after
27 paracetamol overdose. BMJ 1991 Jul 27;303(6796):221-223.

28
29 (24) Izumi S, Langley PG, Wendon J, Ellis AJ, Pernambuco RB, Hughes RD, et al. Coagulation factor V
30 levels as a prognostic indicator in fulminant hepatic failure. Hepatology 1996 Jun;23(6):1507-1511.

31
32 (25) Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic
33 failure: an assessment of the King's criteria. Journal of Hepatology 1997;26(1):62.

34
35 (26) Bernal W, Wendon J, Rela M, Heaton N, Williams R. Use and outcome of liver transplantation in
36 acetaminophen-induced acute liver failure. Hepatology 1998 Apr;27(4):1050-1055.

37
38 (27) Mitchell I, Bihari D, Chang R, Wendon J, Williams R. Earlier identification of patients at risk from
39 acetaminophen-induced acute liver failure. Crit.Care Med. 1998 Feb;26(2):279-284.

40
41 (28) Bernal W, Wendon J. More on serum phosphate and prognosis of acute liver failure [4].
42 Hepatology 2003 01 Aug;38(2):533-534.

43
44 (29) Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced
45 acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005
46 Dec;42(6):1364-1372.

47
48 (30) Schmidt LE, Larsen FS. Prognostic implications of hyperlactatemia, multiple organ failure, and
49 systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver
50 failure. Crit.Care Med. 2006 Feb;34(2):337-343.

51
52 (31) Zaman MB, Hoti E, Qasim A, Maguire D, McCormick PA, Hegarty JE, et al. MELD score as a
53 prognostic model for listing acute liver failure patients for liver transplantation. Transplant.Proc.
54 2006 Sep;38(7):2097-2098.

55
56
57
58
59
60

- 1
2
3 (32) Bates CM, Kochar N, Davidson JS, Hayes PC, Simpson KJ. Blood lactate as a predictor of poor
4 prognosis in acute liver failure in acetaminophen overdose. *Hepatology* 2007;46(4):615A.
5
6
7 (33) Bernal W, Auzinger G, Sizer E, Wendon J. Early prediction of outcome of acute liver failure using
8 bedside measurement of interleukin-6. *Hepatology* 2007;46(4 Supplement 1):617A.
9
10 (34) Trey C, Davidson CS. The management of fulminant hepatic failure. *Prog.Liver Dis.* 1970;3:282-
11 298.
12
13 (35) Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in
14 the evaluation of diagnostic tests. *Ann.Thorac.Surg.* 2005 Jan;79(1):16-20.
15
16
17 (36) Newsome PN, Henderson NC, Germain L, Ludlam CA, Simpson KJ. Prothrombin time to assess
18 fulminant hepatic failure. *Lancet* 2001 Dec 22-29;358(9299):2172.
19
20
21 (37) O'Grady JG. Prognostication in acute liver failure: A tool or an anchor?. *Liver Transplantation*
22 2007 Jun;13(6):786-787.
23
24 (38) O'Grady JG. Broadening the view of acetaminophen hepatotoxicity. *Hepatology* 2005
25 Dec;42(6):1252-1254.
26
27
28 (39) Makin A, Williams R. Paracetamol hepatotoxicity and alcohol consumption in deliberate and
29 accidental overdose. *QJM* 2000 Jun;93(6):341-349.
30
31 (40) Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic
32 inflammatory response syndrome in acute liver failure. *Hepatology* 2000 Oct;32(4 Pt 1):734-739.
33
34 (41) Cholongitas EB, Betrossian A, Leandro G, Shaw S, Patch D, Burroughs AK. King's criteria, APACHE
35 II, and SOFA scores in acute liver failure. *Hepatology* 2006 author reply 882; Apr;43(4):881.
36
37
38 (42) Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe a
39 cetaminophen-induced hepatotoxicity. *Hepatology* 2002 Sep;36(3):659-665.
40
41
42 (43) Gow PJ, Sood S, Angus PW. Serum phosphate as a predictor of outcome in acetaminophen-
43 induced fulminant hepatic failure. *Hepatology* 2003 author reply 712; Mar;37(3):711-712.
44
45
46 (44) Ng KL, Davidson JS, Bathgate AJ. Serum phosphate is not a reliable early predictor of outcome in
47 paracetamol induced hepatotoxicity. *Liver Transplantation* 2004 Jan;10(1):158-159.
48
49 (45) Macquillan GC, Seyam MS, Nightingale P, Neuberger JM, Murphy N. Blood lactate but not serum
50 phosphate levels can predict patient outcome in fulminant hepatic failure. *Liver Transplantation*
51 2005 Sep;11(9):1073-1079.
52
53 (46) Wiesner RH. MELD/PELD and the allocation of deceased donor livers for status 1 recipients with
54 acute fulminant hepatic failure, primary nonfunction, hepatic artery thrombosis, and acute Wilson's
55 disease. *Liver Transplantation* 2004 Oct;10(10 SUPPL. 2):S17-S22.
56
57
58 (47) Dhiman RK, Jain S, Maheshwari U, Bhalla A, Sharma N, Ahluwalia J, et al. Early indicators of
59 prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease
60 (MELD) and King's College Hospital criteria. *Liver Transplantation* 2007 Jun;13(6):814-821.

1
2
3 (48) Katoonizadeh A, Decaestecker J, Wilmer A, Aerts R, Verslype C, Vansteenbergen W, et al. MELD
4 score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver
5 International 2007 Apr;27(3):329-334.
6
7

8 (49) Wei G, Bergquist A, Broome U, Lindgren S, Wallerstedt S, Almer S, et al. Acute liver failure in
9 Sweden: Etiology and outcome. J.Intern.Med. 2007 Sep;262(3):393-401.
10

11 (50) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung
12 injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome
13 Network. N.Engl.J.Med. 2000 May 4;342(18):1301-1308.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5,6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Figure 1
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7-9

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	12, Table 3
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	12, Table 3
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	19
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	17
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Figure 2
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Table 2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Table 3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Table 3
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Table 3
DISCUSSION			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47


Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18-21
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1


For Peer Review

- Adult patients (aged > 16 years) presenting with acute severe liver injury or ALF attributed to paracetamol hepatotoxicity
- Cohort studies
- Included >25 patients with paracetamol hepatotoxicity
- Mortality data recorded
- Data for death and liver transplantation considered separately

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3 Summary receiver operator curve (SROC) of studies evaluating the original KCC
AUC: Area under the curve; SE: Standard Error; Q: heterogeneity

710x564mm (96 x 96 DPI)

view